Ratings of l-dopa-induced dyskinesia in the unilateral 6-ohda lesion model of parkinson’s disease in rats and mice

Current Protocols in Neuroscience

Volumn 41, Issue 1, 2007, Pages 1-23

  Angela Cenci, M ^a   Lundblad, Martin ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

6 hydroxydopamine; Akinesia; Dyskinesia; Hyperkinesia; L DOPA; Mouse; Parkinson s disease; Rat

Indexed keywords

EID: 85089415381     PISSN: 19348584     EISSN: 19348576     Source Type: Journal    
DOI: 10.1002/0471142301.ns0925s41     Document Type: Article

References (41)

1. Ahlskog, J.E. and Muenter, M.D., 2001. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16:448-458.
2. Andersson, M., Hilbertson, A., and Cenci, M.A. 1999. Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol. Dis. 6:461-474.
3. Bishop, C., Taylor, J.L., Kuhn, D.M., Eskow, K.L., Park, J.Y., and Walker, P.D. 2006. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci. 23:2669-2676.
4. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., and Del Tredici, K. 2004. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 318:121-134.
5. Carta, M., Lindgren, H.S., Lundblad, M., Stancampiano, R., Fadda, F., and Cenci, M.A. 2006. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96:1718-1727.
6. Cenci, M.A. 2007. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 30:236-243.
7. Cenci, M.A. and Lundblad, M. 2005. Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease. In Animal models of movement disorders (M. LeDoux ed), pp 193-2008. Elsevier Academic Press, San Diego.
8. Cenci, M.A. and Lundblad, M. 2006. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 99:381-392.
9. Cenci, M.A., Campbell, K., and Bjorklund, A. 1993. Neuropeptidemessenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: Differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphinmessengerRNAlevels. Neuroscience 57:275-296.
10. Cenci, M.A., Lee, C.S., and Bjorklund, A. 1998. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:2694-2706.
11. Cenci, M.A., Whishaw, I.Q., and Schallert, T. 2002. Animal models of neurological deficits: How relevant is the rat? Nat. Rev. Neurosci. 3:574-579.
12. Da Prada, M., Kettler, R., Zurcher, G., Schaffner, R., and Haefely, W.E. 1987. Inhibition of decarboxylase and levels of dopa and 3-Omethyldopa: A comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur. Neurol. 27:9-20.
13. Dekundy, A., Lundblad, M., Danysz, W., and Cenci, M.A. 2007. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model. Behav. Brain Res. 179:76-89.
14. Delfino, M.A., Stefano, A.V., Ferrario, J.E., Taravini, I.R., Murer, M.G., and Gershanik, O.S. 2004. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav. Brain Res. 152:297-306.
15. Fahn, S. 2000. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47:S2-S9.
16. Fahn, S. 2003. Description of Parkinson’s disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 991:1-14.
17. Iancu, R., Mohapel, P., Brundin, P., and Paul, G. 2005. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav. Brain Res. 162:1-10.
18. Lee, C.S., Cenci, M.A., Schulzer, M., and Bjorklund, A. 2000. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain 123:1365-1379.
19. Lindgren, H.S., Rylander, D., Ohlin, K.E., Lundblad, M., and Cenci, M.A. 2007. The “motor complication syndrome” in rats with 6-OHDA lesions treated chronically with L-DOPA: Relation to dose and route of administration. Behav. Brain Res. 177:150-159.
20. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., and Cenci, M.A. 2002. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur. J. Neurosci. 15:120-132.
21. Lundblad, M., Picconi, B., Lindgren, H., and Cenci, M.A. 2004. Amodel of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 16:110-123.
22. Lundblad, M., Usiello, A., Carta, M., Hakansson, K., Fisone, G., and Cenci, M.A. 2005. Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia. Exp. Neurol. 194:66-75.
23. Mazzella, L., Yahr, M.D., Marinelli, L., Huang, N., Moshier, E., and Di Rocco, A. 2005. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson’s disease on L-dopa monotherapy. Parkinsonism Relat. Disord. 11:151-155.
24. Meissner, W., Ravenscroft, P., Reese, R., Harnack, D., Morgenstern, R., Kupsch, A., Klitgaard, H., Bioulac, B., Gross, C.E., Bezard, E., and Boraud, T. 2006. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 22:586-598.
25. Mitsumoto, Y., Watanabe, A., Mori, A., and Koga, N. 1998. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTPtreated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248:660-663.
26. Nutt, J.G., Woodward, W.R., Carter, J.H., and Gancher, S.T. 1992. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch. Neurol. 49:1123-1130.
27. Pinna, A., Pontis, S., and Morelli, M. 2006. Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav. Brain Res. 171:175-178.
28. Popovic, N., Fasano, S., Svensson, A., and Cenci, M.A. The profiles of lesion-induced motor deficit and striatal responsiveness to L-DOPA are dependent on the site of 6-hydroxydopamine injection in the mouse. Submitted for publication.
29. Rajput, A.H., Fenton, M.E., Birdi, S., Macaulay, R., George, D., Rozdilsky, B., Ang, L.C., Senthilselvan, A., and Hornykiewicz, O. 2002. Clinical-pathological study of levodopa complications. Mov. Disord. 17:289-296.
30. Rousselet, E., Joubert, C., Callebert, J., Parain, K., Tremblay, L., Orieux, G., Launay, J.M., Cohen- Salmon, C., and Hirsch, E.C. 2003. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol. Dis. 14:218-228.
31. Sauer, H. and Oertel, W.H. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415.
32. Schallert, T. and Tillerson, J.L. 2000. Intervention strategies for degeneration of dopamine neurons in parkinsonism: Optimizing behavioural assessment of outcome. In Central nervous system diseases (D.F. Emerich, R.L.I Dean, P.R. Sanberg, eds), pp 131-151. Humana Press Totowa, N.J.
33. Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L., and Bland, S.T. 2000. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777-787.
34. Shen, H., Kannari, K., Yamato, H., Arai, A., and Matsunaga, M. 2003. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopaminelesioned rats. Tohoku J. Exp. Med. 199:149-159.
35. Shimohama, S., Sawada, H., Kitamura, Y., and Taniguchi, T. 2003. Disease model: Parkinson’s disease. Trends Mol. Med. 9:360-365.
36. Stefanova, N., Lundblad, M., Tison, F., Poewe, W., Cenci, M.A., and Wenning, G.K. 2004. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol. Dis. 15:630-639.
37. Steiner H. and Kitai, S.T. 2001. Unilateral striatal dopamine depletion: Time-dependent effects on cortical function and behavioural correlates. Eur. J. Neurosci. 14:1390-1404.
38. Ungerstedt, U. 1968. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5:107-110.
39. Westin, J.E., Andersson, M., Lundblad, M., and Cenci, M.A. 2001. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson’s disease. Eur. J. Neurosci. 14:1171-1176.
40. Winkler, C., Kirik, D., Bjorklund, A., and Cenci, M.A. 2002. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson’s disease: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10:165-186.
41. Zarow, C., Lyness, S.A., Mortimer, J.A., and Chui, H.C. 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60:337-341.